The AirCurve 10 CS PaceWave is an adaptive servo-ventilator specifically designed to treat patients exhibiting central sleep apnea (CSA), mixed sleep apnea and periodic breathing, with or without obstructive sleep apnea
Featuring the most clinically-studied ASV algorithm, AirCurve 10 CS PaceWave is the only adaptive servo-ventilator that targets the patient’s own recent minute ventilation.
The device also features built-in wireless connectivity** so you can stay more connected to your patients than ever before.
** Wireless communication depends on network availability
ASVAuto mode adapts to a patient’s ventilatory and upper airway stability needs on a breath-by-breath basis. By treating central breathing disorders with auto-adjusting Pressure Support and upper airway obstruction with auto-adjusting EPAP, it rapidly stabilises breathing and blood gases helping improve sleep quality.1,2
PaceWave is the most clinically studied ASV therapy.
In ASV mode, the EPAP can be manually titrated to set the optimal fixed EPAP to keep the upper airway open.
|AirCurve 10 CS PaceWave|
|Trigger and cycle|
|Enhanced Climate Control Auto|
|Vsync leak management|
|Dimensions (H x W x D) (Device and water tub)||4.57" x 10.04" x 5.91"|
|Air filter||Standard: Average arrestance: >75% for ~7 micron dust||Hypoallergenic: Efficiency: >98% for ~7-8 micron dust. >80% for ~0.5 micron dust|
|Aircraft use||Meets Federal Aviation Administration requirements for all phases of air travel.|
|Operating pressure range||3 to 25 cm H2O|
|Sound (Declared dual-number noise emission values in accordance with ISO 4871:1996.)
|Pressure level measured according to ISO 17510-1:2007 (CPAP mode):|
|SlimLine or Standard air tubing||26.6 dBA with uncertainty of 2 dBA|
|Power level measured according to ISO 17510-1:2007 (CPAP mode):|
|SlimLine or Standard air tubing||34.6 dBA with uncertainty of 2 dBA|
|Air tubing||ClimateLineTM Air||SlimLineTM||Standard|
|Electromagnetic compatibility||Complies with all EMC requirements according to IEC60601-1-2:2007 for residential, commercial and light industry environments. It is recommended that mobile communication devices be kept at least 1m away.|
IMPORTANT NOTE: ASV therapy is contraindicated in patients with chronic, symptomatic heart failure (NYHA 2-4) with reduced left ventricular ejection fraction (LVEF ≤ 45%) and moderate to severe predominant central sleep apnea.